載入中
PMV Pharmaceuticals, Inc. operates as a precision oncology company focused on discovering and developing both small molecule and tumor-agnostic therapies to address p53 mutations in cancer patients. Their leading experimental drug, PC14586, is a small molecule designed to correct the p53 protein specifically when it contains the Y220C mutation, thereby restoring its natural, functional state. The company is also progressing a pipeline of other programs targeting various mutant p53 forms, including Wild-type p53 Induced-Phosphatase, R282W, R273H, and other prevalent p53 hotspot mutations. Originally known as PJ Pharmaceuticals, Inc., the firm rebranded to PMV Pharmaceuticals, Inc. in July 2013. The company was founded in 2013 and has its main operational base in Cranbury, New Jersey.
前收盤價
US$1.52
+US$0.03 · +2.01%
盤中時間採用ET。市場資料可能有所延遲。
PMV Pharmaceuticals, Inc. operates as a precision oncology company focused on discovering and developing both small molecule and tumor-agnostic therapies to address p53 mutations in cancer patients. Their leading experimental drug, PC14586, is a small molecule designed to correct the p53 protein specifically when it contains the Y220C mutation, thereby restoring its natural, functional state. The company is also progressing a pipeline of other programs targeting various mutant p53 forms, including Wild-type p53 Induced-Phosphatase, R282W, R273H, and other prevalent p53 hotspot mutations. Originally known as PJ Pharmaceuticals, Inc., the firm rebranded to PMV Pharmaceuticals, Inc. in July 2013. The company was founded in 2013 and has its main operational base in Cranbury, New Jersey.
日內區間
目前US$1.52
52週區間
目前US$1.52
盤中時間採用ET。市場資料可能有所延遲。
PMV Pharmaceuticals, Inc. operates as a precision oncology company focused on discovering and developing both small molecule and tumor-agnostic therapies to address p53 mutations in cancer patients. Their leading experimental drug, PC14586, is a small molecule designed to correct the p53 protein specifically when it contains the Y220C mutation, thereby restoring its natural, functional state. The company is also progressing a pipeline of other programs targeting various mutant p53 forms, including Wild-type p53 Induced-Phosphatase, R282W, R273H, and other prevalent p53 hotspot mutations. Originally known as PJ Pharmaceuticals, Inc., the firm rebranded to PMV Pharmaceuticals, Inc. in July 2013. The company was founded in 2013 and has its main operational base in Cranbury, New Jersey.
日內區間
目前US$1.52
52週區間
目前US$1.52
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | — | 114.4萬 USD | 125.7萬 USD | 65萬 USD | 128.1萬 USD |
| 毛利 | — | −114.4萬 USD | −125.7萬 USD | −65萬 USD | −128.1萬 USD |
| 研究與開發 | 6987.7萬 USD | 5738.3萬 USD | 5462.8萬 USD | 5167.3萬 USD | 3618.6萬 USD |
| 銷售、一般及管理費用 | 1632.9萬 USD | 2692.1萬 USD | 2424.7萬 USD | 2471.7萬 USD | 2082.6萬 USD |
| 營業費用 | 8620.6萬 USD | 8430.4萬 USD | 7887.5萬 USD | 7639萬 USD | 5701.2萬 USD |
| 利息收入 | 633.7萬 USD | 1065.5萬 USD | 1117.1萬 USD | 362.7萬 USD | 44.9萬 USD |
| 折舊和攤銷 | 13.3萬 USD | 114.4萬 USD | 125.7萬 USD | 31.5萬 USD | 30.7萬 USD |
| 營業利益 | −8620.6萬 USD | −8544.8萬 USD | −8013.2萬 USD | −7704萬 USD | −5829.3萬 USD |
| 淨利 | −7774.2萬 USD | −5870.9萬 USD | −6896萬 USD | −7331.7萬 USD | −5784.6萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
評級樣本有限，僅4項
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI179.93萬0.00%2.3兆 USD0.03%US$381.94+0.63%
Vanguard Extended Market ETFVXF54.74萬0.00%954億 USD0.05%US$235+0.80%
iShares Micro-Cap ETFIWC22.66萬0.02%13.17億 USD0.60%US$183+0.11%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM11萬0.10%1.17億 USD0.73%US$15.9402+0.25%
Avantis Total Equity Markets ETF 1AVTM7026.84—7.94億 USD0.23%US$55.6085+0.56%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAvantis Total Equity Markets ETF 1AVTMAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
